@ . Euripidis tragoediae septendecim ex quibus quaedam habent commentaria ; et sunt hae : ecuba, Orestes Phoenisse Medea, Hippolytus, Alcestis, Andromache. Supplices, Iphigenia im Aulide. Iphigenia in Tauris, Rhesus, Troades, Bacchae, Cyclops, Heraclidae, Helena, Ion

Numérisation partielle de reliure

@ . Euripidis tragoediae septendecim ex quibus quaedam habent commentaria ; et sunt hae : ecuba, Orestes Phoenisse Medea, Hippolytus, Alcestis, Andromache. Supplices, Iphigenia im Aulide. Iphigenia in Tauris, Rhesus, Troades, Bacchae, Cyclops, Heraclidae, Helena, Ion

Numérisation partielle de reliure

Immunochemical characterization of two antigens recognized by new monoclonal antibodies against human colon carcinoma.

Two different monoclonal antibodies (MAb), called L-D1 and L-C5, were produced after immunization with either intact cells or the methanol phase of glycolipid extracts, respectively, from the same human colon carcinoma line, LoVo. As determined by an antibody-binding radioimmunoassay (RIA) on intact cells, MAb L-D1 and MAb L-C5 were highly reactive with all five colon carcinoma lines tested and with only one out of the 21 cell lines of various tissue origin tested. No reactivity of either MAb was observed with peripheral blood lymphocytes, granulocytes, or erythrocytes from healthy donors of various blood groups. Both MAb were tested in competitive binding experiments with an anti-CEA MAb from our laboratory (CEA 35) and with two previously described anti-colon carcinoma MAb from the Wistar Institute called 1083-17-1A (17-1A) and NS-19.9. In competitive binding experiments, MAb L-D1 was inhibited by MAb 17-1A and reciprocally, whereas MAb L-C5 was not inhibited by any of the other MAb tested. MAb L-D1 precipitated a major protein band with an apparent molecular weight (MW) of 41 kilodaltons (kD); interestingly, MAb 17-1A, which was reported to react with an uncharacterized antigen, precipitated the same protein band of 41 kD. This was confirmed with immunodepletion experiments. Furthermore, after treatment of the colon carcinoma cell line with tunicamycin, both MAb L-D1 and 17-1A precipitated a protein band of 35 kD. This shift of 6 kD suggests that the glycoprotein recognized by these 2 MAb contains two to three N-linked carbohydrate side chains. MAb L-C5 precipitated a group of three to four protein bands ranging from 43 to 53 kD that were not modified by tunicamycin treatment. A preliminary study conducted by using immunoperoxidase labeling on frozen sections of primary colon carcinoma showed that the two new MAb react strongly with these tumors, but also weakly with the normal adjacent mucosa, as did the other anti-colon carcinoma MAb tested.

Joannis Joviani Pontani Opera omnia, soluta oratione composita Nomina librorum qui in hisse tribus partibus continentur, à tergo hujus paginae notatae reperiuntur

Comprend : Centum Ptolemaei Sententiae ad Syrum fratrem a Pontano è graeco in latinum tralatae, atque expositae

Joannis Joviani Pontani Opera omnia, soluta oratione composita Nomina librorum qui in hisse tribus partibus continentur, à tergo hujus paginae notatae reperiuntur

Comprend : Centum Ptolemaei Sententiae ad Syrum fratrem a Pontano è graeco in latinum tralatae, atque expositae

Reliure de : Hieronymi Cardani,... De Subtilitate libri XXI...

Numérisation partielle de reliure

[Illustration de L'Histoire de la Terre neuve du Péru en l'Inde occidentale, traduite d'italien en francoys par Jacques Gohory] / [Non identifié] ; Jacques Gohory, trad.

Comprend : [Planche dépliante avec deux cartes du Pérou] [Cote : BNF C125287]

[Illustration de Tariffa de pesi e mesure] / [Non identifié] ; Bartholomeo di Paxi, aut. du texte

Comprend : [ Page de titre avec figures. Clerc enseignant (Bartholomeo Paxi?) les poids et mesures. XVIè siècle.] [ Cote : BNF B 40404. ]

Event-related potentials and changes of brain rhythm oscillations during working memory activation in patients with first-episode psychosis.

Background: Earlier contributions have documented significant changes in sensory, attention-related endogenous event-related potential (ERP) components and θ band oscillatory responses during working memory activation in patients with schizophrenia. In patients with first-episode psychosis, such studies are still scarce and mostly focused on auditory sensory processing. The present study aimed to explore whether subtle deficits of cortical activation are present in these patients before the decline of working memory performance. Methods: We assessed exogenous and endogenous ERPs and frontal θ event-related synchronization (ERS) in patients with first-episode psychosis and healthy controls who successfully performed an adapted 2-back working memory task, including 2 visual n-backworking memory tasks as well as oddball detection and passive fixation tasks. Results: We included 15 patients with first-episode psychosis and 18 controls in this study. Compared with controls, patients with first-episode psychosis displayed increased latencies of early visual ERPs and phasic θ ERS culmination peak in all conditions. However, they also showed a rapid recruitment of working memory-related neural generators, even in pure attention tasks, as indicated by the decreased N200 latency and increased amplitude of sustained θ ERS in detection compared with controls. Limitations: Owing to the limited sample size, no distinction was made between patients with first-episode psychosis with positive and negative symptoms. Although we controlled for the global load of neuroleptics, medication effect cannot be totally ruled out. Conclusion: The present findings support the concept of a blunted electroencephalographic response in patients with first-episode psychosis who recruit the maximum neural generators in simple attention conditions without being able to modulate their brain activation with increased complexity of working memory tasks.

[Illustrations de Le Decameron] / Titien, dess. et peint.; Bonenfant, grav. ; Jean Boccace, aut. du texte

Comprend : [Portrait en reg. folio I : portrait de l'auteur, Jean Boccace, dessiné par P. Jude et gravé par Bonenfant d'après une peinture de Titien.] Johannes Boccatius. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. folio I : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. folio xlviii : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. en reg. folio lxxi : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. en reg. folio lxxiiii : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. en reg. folio xcv : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. avant folio cxv : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. folio cxxviii : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. en reg. folio clxvii : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. en reg. folio ccvii: Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601] ; [Fig. folio ccxxxiiii : Jean Boccace rédigeant son livre.] Bocace. [Cote : Res Y2 402/Microfilm R 1601]

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in this setting. The study was designed as multicenter, randomized phase II trial, preceded by a lead-in safety phase. The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily). Overall, 28 patients were screened, and 26 patients were enrolled. Five dose levels were explored. DLTs, mainly myelosuppression, occurred in 10 patients. Grade 3 or 4 neutropenia was recorded in 7 patients (26.9%) and thrombocytopenia in 11 patients (42.3%). No significant effect of CCNU coadministration on dasatinib pharmacokinetics was found. Median progression-free survival (PFS) was 1.35 months (95% confidence interval: 1.2-1.4) and 6-month PFS was 7.7%. In this phase I study of recurrent glioblastoma patients, the combination of CCNU and dasatinib showed significant hematological toxicities and led to suboptimal exposure to both agents.

Ruling out coronary artery disease in primary care: development and validation of a simple prediction rule.

BACKGROUND: Chest pain can be caused by various conditions, with life-threatening cardiac disease being of greatest concern. Prediction scores to rule out coronary artery disease have been developed for use in emergency settings. We developed and validated a simple prediction rule for use in primary care. METHODS: We conducted a cross-sectional diagnostic study in 74 primary care practices in Germany. Primary care physicians recruited all consecutive patients who presented with chest pain (n = 1249) and recorded symptoms and findings for each patient (derivation cohort). An independent expert panel reviewed follow-up data obtained at six weeks and six months on symptoms, investigations, hospital admissions and medications to determine the presence or absence of coronary artery disease. Adjusted odds ratios of relevant variables were used to develop a prediction rule. We calculated measures of diagnostic accuracy for different cut-off values for the prediction scores using data derived from another prospective primary care study (validation cohort). RESULTS: The prediction rule contained five determinants (age/sex, known vascular disease, patient assumes pain is of cardiac origin, pain is worse during exercise, and pain is not reproducible by palpation), with the score ranging from 0 to 5 points. The area under the curve (receiver operating characteristic curve) was 0.87 (95% confidence interval [CI] 0.83-0.91) for the derivation cohort and 0.90 (95% CI 0.87-0.93) for the validation cohort. The best overall discrimination was with a cut-off value of 3 (positive result 3-5 points; negative result <or= 2 points), which had a sensitivity of 87.1% (95% CI 79.9%-94.2%) and a specificity of 80.8% (77.6%-83.9%). INTERPRETATION: The prediction rule for coronary artery disease in primary care proved to be robust in the validation cohort. It can help to rule out coronary artery disease in patients presenting with chest pain in primary care.